Tumor lysis syndrome risk factors: Difference between revisions
Jump to navigation
Jump to search
Nazia Fuad (talk | contribs) |
|||
| (7 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Tumor lysis syndrome}} | {{Tumor lysis syndrome}} | ||
{{CMG}} {{AE}} {{MJK}} | {{CMG}} {{AE}} {{MJK}} {{N.F}} | ||
==Overview== | ==Overview== | ||
The most potent risk factor in the development of tumor lysis syndrome after initiating [[chemotherapy]] is [[kidney disease]]. Other risk factors include [[dehydration]], hematologic tumors, and solid tumors. | The most potent risk factor in the development of tumor lysis syndrome after initiating [[chemotherapy]] is [[kidney disease]]. Other risk factors include [[dehydration]], hematologic tumors, and solid tumors. | ||
==Risk Factors== | ==Risk Factors== | ||
The followings are risk factors for developing tumor lysis syndrome after initiating chemotherapy: | The followings are risk factors for developing tumor lysis syndrome after initiating chemotherapy:<ref name="urlwww.asn-online.org">{{cite web |url=https://www.asn-online.org/education/distancelearning/curricula/onco/Chapter4.pdf |title=www.asn-online.org |format= |work= |accessdate=}}</ref> | ||
* | === Common Risk Factors === | ||
* Common risk factors in the development of tumor lysis syndrome include:<ref name="pmid25938028">{{cite journal |vauthors=Mirrakhimov AE, Voore P, Khan M, Ali AM |title=Tumor lysis syndrome: A clinical review |journal=World J Crit Care Med |volume=4 |issue=2 |pages=130–8 |date=May 2015 |pmid=25938028 |pmc=4411564 |doi=10.5492/wjccm.v4.i2.130 |url=}}</ref> | |||
:*[[ | ** [[acute lymphoblastic leukemia]] | ||
** [[Non-Hodgkin lymphoma]] | |||
** [[Burkitt's lymphoma|Burkitts lymphoma]] | |||
** Older age | |||
** [[Dehydration]] | |||
** [[Non-steroidal anti-inflammatory drug|Non-steroidal anti-inflammatory drugs]] | |||
** [[ACE inhibitor|Angiotensin converting enzyme inhibitors]] | |||
** [[angiotensin receptor blockers]] | |||
=== Less Common Risk Factors === | |||
* Less common risk factors in the development of TLS include:<ref name="pmid25938028" /> | |||
** [[Multiple myeloma]] | |||
** [[Melanoma]] | |||
** [[Breast cancer]] | |||
**[[Ovarian cancer]] | |||
**[[Hepatocellular carcinoma]] | |||
**[[Lung cancer]] | |||
**[[Sarcomas]] | |||
==References== | ==References== | ||
| Line 31: | Line 38: | ||
[[Category:Blood]] | [[Category:Blood]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
Latest revision as of 19:33, 27 August 2018
|
Tumor lysis syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tumor lysis syndrome risk factors On the Web |
|
American Roentgen Ray Society Images of Tumor lysis syndrome risk factors |
|
Risk calculators and risk factors for Tumor lysis syndrome risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Nazia Fuad M.D.
Overview
The most potent risk factor in the development of tumor lysis syndrome after initiating chemotherapy is kidney disease. Other risk factors include dehydration, hematologic tumors, and solid tumors.
Risk Factors
The followings are risk factors for developing tumor lysis syndrome after initiating chemotherapy:[1]
Common Risk Factors
- Common risk factors in the development of tumor lysis syndrome include:[2]
Less Common Risk Factors
- Less common risk factors in the development of TLS include:[2]
References
- ↑ "www.asn-online.org" (PDF).
- ↑ 2.0 2.1 Mirrakhimov AE, Voore P, Khan M, Ali AM (May 2015). "Tumor lysis syndrome: A clinical review". World J Crit Care Med. 4 (2): 130–8. doi:10.5492/wjccm.v4.i2.130. PMC 4411564. PMID 25938028.